Get startedLog in
    Picture of X4 Pharmaceuticals logo

    XFOR — X4 Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapMomentum Trap
    All News

    Brief: X4 Pharmaceuticals And Norgine Enter Into Exclusive Licensing Agreement To Commercialize Mavorixafor In Europe, Australia, And New Zealand

    Picture of X4 Pharmaceuticals logoX4 Pharmaceuticals
    13/01/2025 13:46
    Jan 13 (Reuters) - X4 Pharmaceuticals Inc  XFOR.O :
    * X4 PHARMACEUTICALS AND NORGINE ENTER INTO EXCLUSIVE
LICENSING
AGREEMENT TO COMMERCIALIZE MAVORIXAFOR IN EUROPE, AUSTRALIA, AND
NEW ZEALAND
    * TO RECEIVE €28.5 MILLION UPFRONT, UP TO €226 MILLION IN
MILESTONES
    * TO SUBMIT MAA TO EMA FOR MAVORIXAFOR IN WHIM SYNDROME

Source text:  ID:nGNX503rCz 
Further company coverage:  XFOR.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on X4 Pharmaceuticals

    See all news